---
title: "ASPrin in Reducing Events in the Elderly (ASPREE) & ASPREE-XT"
id: "4251"
type: "cohort"
slug: "asprin-in-reducing-events-in-the-elderly-aspree"
published_at: "2022-12-13T18:17:54+00:00"
modified_at: "2024-11-27T16:05:35+00:00"
url: "https://dss.niagads.org/cohorts/asprin-in-reducing-events-in-the-elderly-aspree/"
markdown_url: "https://dss.niagads.org/cohorts/asprin-in-reducing-events-in-the-elderly-aspree.md"
excerpt: "ASPREE is a randomized, double-blind, placebo-controlled clinical trial investigating the effects of 100mg of daily low-dose aspirin in 19,114 healthy older adults, aged ≥70 years (≥65 years for US participants) at enrollment. ASPREE-XT is an ongoing observational follow-up study to..."
taxonomy_cohort_categories:
  - "ADSP"
taxonomy_cohort_countries:
  - "Australia"
  - "United States of America"
---

Website:

[https://aspree.org/](https://aspree.org/)

## Description

ASPREE is a randomized, double-blind, placebo-controlled clinical trial investigating the effects of 100mg of daily low-dose aspirin in 19,114 healthy older adults, aged ≥70 years (≥65 years for US participants) at enrollment.

ASPREE-XT is an ongoing observational follow-up study to examine the long-term effects of aspirin on various health outcomes, including cancer, dementia, and physical disability. The study also seeks to identify other lifestyle, genetic, environmental, and health-related factors contributing to healthy aging.

Additional details about the adjudication can be found in the ASPREE publication: Ryan, Joanne et al. “Randomized placebo-controlled trial of the effects of aspirin on dementia and cognitive decline.” *Neurology* vol. 95,3 (2020): e320-e331. doi:10.1212/WNL.000000000000927. [PubMed Link](https://pubmed.ncbi.nlm.nih.gov/32213642/)

## Related Datasets

- [NG00067 – ADSP Umbrella](https://dss.niagads.org/datasets/ng00067/) This dataset includes sequencing data and harmonized phenotypes from cohorts sequenced by the Alzheimer’s Disease Sequencing Project and other AD and Related Dementia’s studies. Samples are processed using a common… [Learn more](https://dss.niagads.org/datasets/ng00067/)

## Related Studies

- [sa000001 - Alzheimer’s Disease Sequencing Project (ADSP)](https://dss.niagads.org/studies/sa000001/) Background An initiative in response to the National Alzheimer’s Project Act (NAPA) has been working towards new biological insights and cures for Alzheimer’s Disease (AD) since its introduction by NIH… [Learn more](https://dss.niagads.org/studies/sa000001/)
- [sa000060 - ASPirin in Reducing Events in the Elderly (ASPREE)](https://dss.niagads.org/studies/sa000060/) The ASPREE (ASPirin in Reducing Events in the Elderly) project comprises: a) a multi-center, bi-national randomized controlled trial (RCT) of 19,114 older people in Australia and the US aimed at… [Learn more](https://dss.niagads.org/studies/sa000060/)

## Related Sample Sets

- [snd10093 - ASPREE1 WGS](https://dss.niagads.org/sample-sets/snd10093/) 2,795 samples were sequenced at Kinghorn Centre for Clinical Genomics (KCCG) in Sydney, Australia, on Illumina HiSeqX. CRAM files were sent to GCAD for processing. A total of 2,735 samples… [Learn more](https://dss.niagads.org/sample-sets/snd10093/)
- [snd10094 - ADSP-FUS3 WGS](https://dss.niagads.org/sample-sets/snd10094/) The ADSP-FUS is a National Institute on Aging (NIA) initiative focused on identifying genetic risk and protective variants for late-onset Alzheimer Disease (LOAD). A concern in AD genetic studies is… [Learn more](https://dss.niagads.org/sample-sets/snd10094/)

 ```